← All candidates
No insider filings on record.
6 filings on record.
GTBPGT Biopharma, Inc.
—
$9.00
-22.61% · Sep 15
No insider filings on record.
GT Biopharma, Inc. hasn't reported Form 4 activity yet.
Price · 1Y · dailyNo open-market activity in range
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 3×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what GTBP ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Short % float
Pro
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
No insider transactions on file for GTBP yet.
Context
Wall St
$75.00 avg target
+733.3% vs today · 1 analyst
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
0 of 4 quarters beat
Q2 '26−$3.00 act−$1.00
Q1 '26−$2.75 act−$0.75
Q4 '25−$121.00 act−$115.50
Q3 '25−$20.75 act−$11.25
Coverage
GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should KnowZacks · 03-16GT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks · 03-12EXCLUSIVE: GT Biopharma Achieves Development Milestone for Human Trial for Novel Blood Cancer TherapyBenzinga · 3h agoEXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology RolloutBenzinga · 06-01
The file stays open
6 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice